CHEST:中国结缔组织疾病相关性间质性肺疾病(CTD-ILD)患者的临床特点

2016-01-21 fsy 译 MedSci原创

由于和结缔组织病(CTD)的患病率相关的间质性肺疾病(ILD; CTD-ILD)在中国是未知的,所以研究人员在该研究种分析了中国患者的本疾病的临床特点。研究人员招募了在1999年1月2013年1月之间在上海肺科医院诊断为ILD并治疗的患者,对其病历进行了审查。根据记录,被诊断为CTD的患者进行了鉴定,并进行随访检查最少12个月,直到2013年12月底。在诊断为ILD的2678例患者中,1798(6

在中国,由于与结缔组织病(CTD)相关的间质性肺疾病(ILD; CTD-ILD)的患病率是未知的,所以研究人员在该研究中分析了中国患者的本疾病的临床特点。

研究人员招募了在1999年1月到2013年1月之间在上海肺科医院诊断为ILD并治疗的患者,对其病历进行了审查。根据记录,被诊断为CTD的患者进行了鉴定,并进行随访检查最少12个月,直到2013年12月底。

在诊断为ILD的2678例患者中,1798(67%)例患者被确定为患有CTD-ILD;299例(11.2%)有特发性肺纤维化(IPF)。1044例CTD-ILD患者和178例IPF患者的完整的临床数据可用。研究人员发现,1044例CTD-ILD患者中的332例(32%)患者在最初入院时并没有接受正确的诊断,195(18.7%)例患者表现为持续性的自身抗体阴性结果,262(25.​​1% )例患者在开始入院时表现为自身抗体阴性,然后在随访检查时转为阳性。在被诊断为CTD-ILD的288例患者中,41(14%)例患者显示肺部症状为首发临床表现(PSIM),247(86%)例显示出肺外症状为首发临床表现(PSIM)。对于756例未分化CTD-ILD的患者,PSIM和EPSOM的比例分别为44%和56%。对于表现出PSIM的患者,23例曾被证实CTD-ILD(56%),216例曾未经证实CTD-ILD的患者(65%)在开始入院时没有得到一个准确的诊断,但最终在后续随访检查时被诊断出。

CTD-ILD患者在初始入院时没有得到正确的诊断,可能是因为自身抗体阴性的血清结果和没有明显的肺外症状造成的。也就是说,ILD患者应检查肺外的症状,并在后续检查中测试自身抗体。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837179, encodeId=6922183e179ee, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 23 02:30:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783860, encodeId=60061e83860b5, content=<a href='/topic/show?id=cc9553947a' target=_blank style='color:#2F92EE;'>#CTD-ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5394, encryptionId=cc9553947a, topicName=CTD-ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed May 04 12:30:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050529, encodeId=6783205052942, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 14 07:30:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662574, encodeId=85d116625e475, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Fri May 13 02:30:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661928, encodeId=39021661928e7, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 06 21:30:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933876, encodeId=442819338e67d, content=<a href='/topic/show?id=7c1c2288877' target=_blank style='color:#2F92EE;'>#临床特点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22888, encryptionId=7c1c2288877, topicName=临床特点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Tue Sep 20 14:30:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815748, encodeId=05a31815e482b, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Fri Nov 18 06:30:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61081, encodeId=b5a36108109, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929239, encodeId=862119292395a, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 09 07:30:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59966, encodeId=57965996662, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:18:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837179, encodeId=6922183e179ee, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 23 02:30:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783860, encodeId=60061e83860b5, content=<a href='/topic/show?id=cc9553947a' target=_blank style='color:#2F92EE;'>#CTD-ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5394, encryptionId=cc9553947a, topicName=CTD-ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed May 04 12:30:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050529, encodeId=6783205052942, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 14 07:30:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662574, encodeId=85d116625e475, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Fri May 13 02:30:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661928, encodeId=39021661928e7, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 06 21:30:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933876, encodeId=442819338e67d, content=<a href='/topic/show?id=7c1c2288877' target=_blank style='color:#2F92EE;'>#临床特点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22888, encryptionId=7c1c2288877, topicName=临床特点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Tue Sep 20 14:30:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815748, encodeId=05a31815e482b, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Fri Nov 18 06:30:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61081, encodeId=b5a36108109, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929239, encodeId=862119292395a, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 09 07:30:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59966, encodeId=57965996662, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:18:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-05-04 yang0210
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837179, encodeId=6922183e179ee, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 23 02:30:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783860, encodeId=60061e83860b5, content=<a href='/topic/show?id=cc9553947a' target=_blank style='color:#2F92EE;'>#CTD-ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5394, encryptionId=cc9553947a, topicName=CTD-ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed May 04 12:30:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050529, encodeId=6783205052942, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 14 07:30:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662574, encodeId=85d116625e475, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Fri May 13 02:30:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661928, encodeId=39021661928e7, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 06 21:30:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933876, encodeId=442819338e67d, content=<a href='/topic/show?id=7c1c2288877' target=_blank style='color:#2F92EE;'>#临床特点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22888, encryptionId=7c1c2288877, topicName=临床特点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Tue Sep 20 14:30:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815748, encodeId=05a31815e482b, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Fri Nov 18 06:30:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61081, encodeId=b5a36108109, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929239, encodeId=862119292395a, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 09 07:30:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59966, encodeId=57965996662, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:18:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-06-14 xiangyuzhou971
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837179, encodeId=6922183e179ee, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 23 02:30:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783860, encodeId=60061e83860b5, content=<a href='/topic/show?id=cc9553947a' target=_blank style='color:#2F92EE;'>#CTD-ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5394, encryptionId=cc9553947a, topicName=CTD-ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed May 04 12:30:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050529, encodeId=6783205052942, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 14 07:30:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662574, encodeId=85d116625e475, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Fri May 13 02:30:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661928, encodeId=39021661928e7, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 06 21:30:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933876, encodeId=442819338e67d, content=<a href='/topic/show?id=7c1c2288877' target=_blank style='color:#2F92EE;'>#临床特点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22888, encryptionId=7c1c2288877, topicName=临床特点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Tue Sep 20 14:30:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815748, encodeId=05a31815e482b, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Fri Nov 18 06:30:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61081, encodeId=b5a36108109, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929239, encodeId=862119292395a, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 09 07:30:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59966, encodeId=57965996662, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:18:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837179, encodeId=6922183e179ee, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 23 02:30:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783860, encodeId=60061e83860b5, content=<a href='/topic/show?id=cc9553947a' target=_blank style='color:#2F92EE;'>#CTD-ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5394, encryptionId=cc9553947a, topicName=CTD-ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed May 04 12:30:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050529, encodeId=6783205052942, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 14 07:30:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662574, encodeId=85d116625e475, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Fri May 13 02:30:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661928, encodeId=39021661928e7, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 06 21:30:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933876, encodeId=442819338e67d, content=<a href='/topic/show?id=7c1c2288877' target=_blank style='color:#2F92EE;'>#临床特点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22888, encryptionId=7c1c2288877, topicName=临床特点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Tue Sep 20 14:30:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815748, encodeId=05a31815e482b, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Fri Nov 18 06:30:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61081, encodeId=b5a36108109, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929239, encodeId=862119292395a, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 09 07:30:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59966, encodeId=57965996662, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:18:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-02-06 docwu2019
  6. [GetPortalCommentsPageByObjectIdResponse(id=1837179, encodeId=6922183e179ee, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 23 02:30:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783860, encodeId=60061e83860b5, content=<a href='/topic/show?id=cc9553947a' target=_blank style='color:#2F92EE;'>#CTD-ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5394, encryptionId=cc9553947a, topicName=CTD-ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed May 04 12:30:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050529, encodeId=6783205052942, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 14 07:30:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662574, encodeId=85d116625e475, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Fri May 13 02:30:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661928, encodeId=39021661928e7, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 06 21:30:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933876, encodeId=442819338e67d, content=<a href='/topic/show?id=7c1c2288877' target=_blank style='color:#2F92EE;'>#临床特点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22888, encryptionId=7c1c2288877, topicName=临床特点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Tue Sep 20 14:30:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815748, encodeId=05a31815e482b, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Fri Nov 18 06:30:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61081, encodeId=b5a36108109, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929239, encodeId=862119292395a, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 09 07:30:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59966, encodeId=57965996662, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:18:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1837179, encodeId=6922183e179ee, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 23 02:30:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783860, encodeId=60061e83860b5, content=<a href='/topic/show?id=cc9553947a' target=_blank style='color:#2F92EE;'>#CTD-ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5394, encryptionId=cc9553947a, topicName=CTD-ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed May 04 12:30:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050529, encodeId=6783205052942, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 14 07:30:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662574, encodeId=85d116625e475, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Fri May 13 02:30:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661928, encodeId=39021661928e7, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 06 21:30:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933876, encodeId=442819338e67d, content=<a href='/topic/show?id=7c1c2288877' target=_blank style='color:#2F92EE;'>#临床特点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22888, encryptionId=7c1c2288877, topicName=临床特点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Tue Sep 20 14:30:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815748, encodeId=05a31815e482b, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Fri Nov 18 06:30:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61081, encodeId=b5a36108109, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929239, encodeId=862119292395a, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 09 07:30:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59966, encodeId=57965996662, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:18:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1837179, encodeId=6922183e179ee, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 23 02:30:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783860, encodeId=60061e83860b5, content=<a href='/topic/show?id=cc9553947a' target=_blank style='color:#2F92EE;'>#CTD-ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5394, encryptionId=cc9553947a, topicName=CTD-ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed May 04 12:30:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050529, encodeId=6783205052942, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 14 07:30:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662574, encodeId=85d116625e475, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Fri May 13 02:30:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661928, encodeId=39021661928e7, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 06 21:30:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933876, encodeId=442819338e67d, content=<a href='/topic/show?id=7c1c2288877' target=_blank style='color:#2F92EE;'>#临床特点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22888, encryptionId=7c1c2288877, topicName=临床特点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Tue Sep 20 14:30:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815748, encodeId=05a31815e482b, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Fri Nov 18 06:30:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61081, encodeId=b5a36108109, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929239, encodeId=862119292395a, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 09 07:30:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59966, encodeId=57965996662, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:18:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 李继凯

    文章不错

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1837179, encodeId=6922183e179ee, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 23 02:30:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783860, encodeId=60061e83860b5, content=<a href='/topic/show?id=cc9553947a' target=_blank style='color:#2F92EE;'>#CTD-ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5394, encryptionId=cc9553947a, topicName=CTD-ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed May 04 12:30:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050529, encodeId=6783205052942, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 14 07:30:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662574, encodeId=85d116625e475, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Fri May 13 02:30:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661928, encodeId=39021661928e7, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 06 21:30:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933876, encodeId=442819338e67d, content=<a href='/topic/show?id=7c1c2288877' target=_blank style='color:#2F92EE;'>#临床特点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22888, encryptionId=7c1c2288877, topicName=临床特点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Tue Sep 20 14:30:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815748, encodeId=05a31815e482b, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Fri Nov 18 06:30:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61081, encodeId=b5a36108109, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929239, encodeId=862119292395a, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 09 07:30:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59966, encodeId=57965996662, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:18:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-10-09 Smile2680
  10. [GetPortalCommentsPageByObjectIdResponse(id=1837179, encodeId=6922183e179ee, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jul 23 02:30:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783860, encodeId=60061e83860b5, content=<a href='/topic/show?id=cc9553947a' target=_blank style='color:#2F92EE;'>#CTD-ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5394, encryptionId=cc9553947a, topicName=CTD-ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed May 04 12:30:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050529, encodeId=6783205052942, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 14 07:30:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662574, encodeId=85d116625e475, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Fri May 13 02:30:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661928, encodeId=39021661928e7, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 06 21:30:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933876, encodeId=442819338e67d, content=<a href='/topic/show?id=7c1c2288877' target=_blank style='color:#2F92EE;'>#临床特点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22888, encryptionId=7c1c2288877, topicName=临床特点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Tue Sep 20 14:30:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815748, encodeId=05a31815e482b, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Fri Nov 18 06:30:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61081, encodeId=b5a36108109, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:32:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929239, encodeId=862119292395a, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 09 07:30:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59966, encodeId=57965996662, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:18:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

相关资讯

中国姑娘意大利高烧3月不退 回国医治已发展为罕见严重心内膜炎!

昨天,演员李冰冰终于康复出院,微博上贴出在澳大利亚的看病经历,感叹“不用羡慕国外的月亮比国内圆”。 类似的经历也发生在全家移居意大利的温州姑娘小羽身上,如果不是回到国内看病,她还真不敢想象结果会怎么样。 据《今日早报》24日报道,小羽今年24岁,之前在意大利高烧3个月但却一直查不出原因,不得已赶回浙江到浙大一院就诊,被医生确诊为心内膜炎,医生说她的心脏瓣膜都已经被细菌腐蚀了。 高烧三个月,家

Nature:中国全力推进精准医学

拥有强大的基因组测序能力,千百万的患者,及政府承诺给予的坚定支持:这些都是中国有望带给精准医学新兴领域的宝贵资产。精准医学是指利用基因组学、生理学和其他的数据来为个体量身定制治疗方案。 在美国总统奥巴马宣布启动精准医学计划(Precision Medicine Initiative)一年后,中国当前正在最后确定它自己的更大型的项目计划。但随着一些大学和测序公司组织起来收集及分析这些数据,

BMJ Open:中国非小细胞肺癌发病率和生存率研究

中国大陆缺乏非小细胞肺癌 (NSCLC)发病率和预后的大样本研究,因此研究者对上海NSCLC患者进行了一项研究,探究NSCLC发病率、人口学特征及生存情况,以及影响生存的因素。该前瞻性研究共纳入15 020名患者。研究数据显示,NSCLC粗发病率为54.20/100 000,其中男性55.90/100 000,女性52.39/100 000;校正年龄后NSCLC发病率为39.05/100 000,

中国或将成全球很大试管婴儿市场

参考消息网12月5日报道 外媒称,位于广东省的南方医院说,它为寻求试管婴儿的中国患者提供选择孩子性别以及避免严格审核和令人抓狂排长队的机会。 据路透社12月1日报道,它在为此做广告时必须要小心。中国对国内试管婴儿市场进行严格监管,禁止性别选择,要求准生证和婚姻证明,并且禁止一些更高级的步骤。这些规定促使患者前往海外,或在国内一些不规范医疗机构寻求治疗。 在中国10月份取消了独生子女政策后,

日本医疗再次被评为全球领先,中国位居第…看完我的内心是奔溃的

世界卫生组织(WHO)在最新的报告《World HealthReport》中,从“医疗水平”,“接受医疗服务的难度”,“医药费负担公平性”等方面对世界各国的医疗体系进行了综合比较。 日本因为“高品质的医疗服务”和“医疗负担的平等程度”,“国民平均寿命高”等原因,再次蝉联第一位。中国位居第64位。 其实,日本从政府层面对国民健康加以管理可以追溯到1978年。当时日

Lancet Dia & Endo:中国早发2型糖尿病患者非致命性心血管疾病的危险性增加

2型糖尿病的发病年龄正在逐渐降低。由于非中国早发2型糖尿病患者(这里定义的诊断在<40岁)增加了血管并发症的风险,研究人员调查了在中国早发性 vs 晚发性2型糖尿病对非致命性心血管疾病的影响。研究人员使用了来自中国国家糖化血红蛋白监测系统(CNHSS)的调查数据,其中包括222773例中国2型糖尿病患者,他们在2012年来自于中国的30个省106个城市的630家医院。研究人员记录了人口统计信